Advertisement

Pharmacology of Octreotide

Clinical Implications for Anesthesiologists and Associated Risks

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Anesthesiology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Wilcock A.
        • Twycross R.
        Therapeutic reviews: octreotide.
        J Pain Symptom Manage. 2010; 40: 142-148
        • Mancuso K.
        • Kaye A.D.
        • Boudreaux J.P.
        • et al.
        Carcinoid syndrome and perioperative anesthetic considerations.
        J Clin Anesth. 2011; 23: 329-341
        • Dierdorf S.
        Carcinoid tumor and carcinoid syndrome.
        Curr Opin Anaesthesiol. 2003; 16: 343-347
      1. Sandostatin, Octreotide acetate injection; Prescribing Information. Novartis Pharmaceuticals Corporation, 2012
        • Oberg K.
        • Kvols L.
        • Caplin M.
        • et al.
        Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.
        Ann Oncol. 2004; 15: 966-973
        • Garcia-Tsao G.
        • Bosch J.
        Management of varices and variceal hemorrhage in cirrhosis.
        N Engl J Med. 2010; 362: 823-832
        • Mercadante S.
        • Porzio G.
        Octreotide for malignant bowel obstruction: twenty years after.
        Crit Rev Oncol Hematol. 2012; 83: 388-392
        • Ripamonti C.
        • Mercadante S.
        • Groff L.
        • et al.
        Role of Octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial.
        J Pain Symptom Manage. 2000; 19: 23-34
        • De Conno F.
        • Saita L.
        • Ripamonti C.
        • et al.
        Subcutaneous octreotide in the treatment of pain in advanced cancer patients.
        J Pain Symptom Manage. 1994; 9: 34-38
        • Kalambokis G.
        • Fotopoulos A.
        • Economou M.
        • et al.
        Octreotide in the treatment of refractory ascites of cirrhosis.
        Scand J Gastroenterol. 2006; 41: 118-121
        • Zhou D.X.
        • Zhou H.B.
        • Wang Q.
        • et al.
        The effectiveness of the treatment of octreotide on chylous ascites after liver cirrhosis.
        Dig Dis Sci. 2009; 54: 1783-1788
        • Byram S.W.
        • Gupta R.A.
        • Ander M.
        • et al.
        Effects of continuous octreotide infusion on intraoperative transfusion requirements during orthotopic liver transplantation.
        Transplant Proc. 2015; 47: 2712-2714
        • Owais T.A.
        • Back D.
        • Girdauskas E.
        • et al.
        Postoperative chylothorax: is octreotide a valid therapy?.
        J Case Rep Stud. 2015; 3: 307
        • Woltering E.A.
        • Wright A.E.
        • Stevens M.A.
        • et al.
        Development of effective prophylaxis against intraoperative carcinoid crisis.
        J Clin Anesth. 2016; 32: 189-193
        • Bajwa S.J.
        • Panda A.
        • Kaur G.
        Carcinoid tumors: challenges and considerations during anesthetic management.
        J Scientific Soc. 2015; V42 (Available at:): 132-137
        • Bendelow J.
        • Apps E.
        • Jones L.E.
        • et al.
        Carcinoid syndrome.
        Eur J Surg Oncol. 2008; 34: 289-296
        • Vaughan D.J.
        • Brunner M.D.
        Anesthesia for patients with carcinoid syndrome.
        Int Anesthesiol Clin. 1997; 35: 129-142
        • Orbach-Zinger S.
        • Lombroso R.
        • Eidelman L.A.
        Uneventful spinal anesthesia for a patient with carcinoid syndrome managed with long-acting octreotide.
        Can J Anaesth. 2002; 49: 678-681
        • Farling P.A.
        • Durairaju A.K.
        Remifentanil and anaesthesia for carcinoid syndrome.
        Br J Anaesth. 2004; 92: 893-895
        • Bajwa S.
        • Kulshrestha A.
        Dexmedetomidine: an adjuvant making large inroads into clinical practice.
        Ann Med Health Sci Res. 2013; 3: 475-483
        • Condron M.E.
        • Pommier S.J.
        • Pommier R.F.
        Continuous infusion of octreotide combined with perioperative octreotide bolus does not prevent intraoperative carcinoid crisis.
        Surgery. 2015; 159: 358-367
        • Massimino K.
        • Harrskog O.
        • Pommier S.
        • et al.
        Octreotide LAR and bolus octreotide are insufficient for preventing intraoperative complications in carcinoid patients.
        J Surg Oncol. 2013; 107: 842-846